Skip to main content

Table 1 Therapy protocol: classification of therapy groups and specification of administration of the BN analogues

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues

Therapy groups BN analogues Dose and peptide amount Injection time
Mice with PC-3 tumour xenografts A PBS 2 × 100 μl Days 0 and 14
B DOTA-PEG5k-Lys-BN 2 × 3.0 nmol Days 0 and 14
C 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/3.0 nmol each Days 0 and 14
D 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 14
E 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 7
F 177Lu-DOTA-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 14
Mice without PC-3 tumour xenografts G PBS 2 × 100 μl Days 0 and 14
  H 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/0.3 nmol each Days 0 and 14
  I 177Lu-DOTA-PEG5k-Lys-BN 2 × 20 MBq/3.0 nmol each Days 0 and 14